John Danias
Overview
Explore the profile of John Danias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexopoulos P, Fernandes A, Ghassabi Z, Zambrano R, Vellappally A, Shemuelian E, et al.
Transl Vis Sci Technol
. 2024 Sep;
13(9):23.
PMID: 39297808
Purpose: The lamina cribrosa (LC) is hypothesized to be the site of initial axonal damage in glaucoma with the circumpapillary retinal nerve fiber layer thickness (RNFL-T) widely used as a...
2.
Borras T, Stepankoff M, Danias J
Curr Opin Ophthalmol
. 2023 Dec;
35(2):131-137.
PMID: 38117663
Purpose Of Review: To provide the latest advances on the future use of gene therapy for the treatment of glaucoma. Recent Findings: In preclinical studies, a number of genes have...
3.
Lehrer S, Morello T, Karrasch C, Rheinstein P, Danias J
J Glaucoma
. 2023 Nov;
33(4):240-245.
PMID: 38031296
Prcis: Glucosamine supplementation is common but can be associated with increased intraocular pressure (IOP) and could contribute to the pathogenesis of glaucoma. It may be prudent for ophthalmologists to elicit...
4.
Beardslee L, Halman J, Unser A, Xie Y, Danias J, Bergkvist M, et al.
Bioengineering (Basel)
. 2023 Jun;
10(6).
PMID: 37370610
Glaucoma, where increased intraocular pressure (IOP) leads to damage to the optic nerve and loss of sight, is amongst the foremost causes of irreversible blindness worldwide. In primary open angle...
5.
Filippopoulos T, Danias J, Karmiris E, Megevand G, Rhee D, Gazzard G, et al.
Ophthalmol Glaucoma
. 2023 Jun;
6(6):657-667.
PMID: 37321374
Purpose: To examine the generalizability, discuss limitations, and critically appraise recommendations on the management of primary angle-closure suspects (PACSs) that emerged as a result of recent randomized clinical trials challenging...
6.
Fernandes A, Alexopoulos P, Burgos-Rodriguez A, Martinez M, Ghassibi M, Leskov I, et al.
Invest Ophthalmol Vis Sci
. 2023 Jun;
64(7):3.
PMID: 37261386
Purpose: Rhesus macaques (Macaca mulatta) are the premier nonhuman primate model for studying human health and disease. We investigated if age was associated with clinically relevant ocular features in a...
7.
McDowell C, Kizhatil K, Elliott M, Overby D, van Batenburg-Sherwood J, Millar J, et al.
Invest Ophthalmol Vis Sci
. 2022 Feb;
63(2):12.
PMID: 35129590
Due to their similarities in anatomy, physiology, and pharmacology to humans, mice are a valuable model system to study the generation and mechanisms modulating conventional outflow resistance and thus intraocular...
8.
Gindina S, Barron A, Hu Y, Dimopoulos A, Danias J
Mol Vis
. 2022 Jan;
27:691-705.
PMID: 35002214
Purpose: Tissue plasminogen activator (tPA) prevents steroid-induced reduction in aqueous humor outflow facility; however, its mechanism of action at the trabecular meshwork (TM) remains unclear. Enzymatic and non-enzymatic domains allow...
9.
Gindina S, Hu Y, Barron A, Qureshi Z, Danias J
Exp Eye Res
. 2020 Aug;
199:108179.
PMID: 32739292
Tissue plasminogen activator (tPA) has been shown to prevent steroid-induced reduction in aqueous humor outflow facility via an upregulation in matrix metalloproteinase (Mmp) expression. The purpose of this study was...
10.
Tian Y, Zhang X, Torrejon K, Danias J, Du Y, Xie Y
Adv Biosyst
. 2020 Aug;
4(9):e2000004.
PMID: 32734694
Age-related human trabecular meshwork (HTM) cell loss is suggested to affect its ability to regulate aqueous humor outflow in the eye. In addition, disease-related HTM cell loss is suggested to...